Cardiometabolic risk factors efficacy of semaglutide in the STEP program
Year: 2022
Type: article
Abstract: , improvements in lipid profile, and stabilization of SBP. Overall, across the STEP trials, treatment with semaglutide 2.4 mg versus placebo improved cardiometabolic risk factors associated with obesity, illustrating an effective treatment option for people with overweight (and associated comorbidities) or obesity.
Source: Postgraduate Medicine
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Novo Nordisk
OpenAlex ID: W4317869445
